Daxor Expands Its BVA-100™ Blood Volume Diagnostic to Two New Hospital Systems Adding to Sales Momentum
Rhea-AI Summary
Daxor (DXR) announces expansion of its ezBVA Lab blood volume analysis service to two new health systems. The expansion includes an Arizona-based multi-campus medical center for outpatient nephrology care and a regional health network serving Southwest Iowa, Nebraska, Minnesota, and North Dakota for heart failure outpatient management.
The ezBVA Lab service provides cost-effective blood volume analysis with minimal initial investment and broad reimbursement coverage. The company reports this expansion contributes to their strongest quarter ever in terms of revenue and year-over-year growth.
Positive
- Expansion to two new major health systems
- Company reports best quarter ever in revenue and year-over-year growth
- Broad reimbursement coverage across hospitals and ambulatory care settings
- Minimal initial investment required for healthcare providers
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, DXR gained 0.99%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Healthcare Providers Embrace Blood Volume Analysis (BVA) in Nephrology and Heart Failure Outpatient Care
Oak Ridge, TN, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces expansion of its ezBVA Lab service to two new health systems. Daxor's ezBVA Lab provides cost-effective blood volume analysis, offering comprehensive sample processing with minimal initial investment. The service has broad reimbursement coverage across hospitals and ambulatory care settings.
New wins include:
- A major Arizona-based multi-campus medical center has adopted our BVA technology for outpatient nephrology care with further departments to follow in 2025.
- A regional health network serving communities across Southwest Iowa, Nebraska, Minnesota, and North Dakota has agreed to implement BVA for heart failure outpatient management.
“Our BVA platform is a critical diagnostic tool that redefines outpatient care by providing real-time insights into a patient's volume status. By enabling early detection of fluid imbalances and cardiovascular risks, BVA empowers clinicians to intervene proactively, potentially preventing costly hospitalizations, reducing emergency interventions, and personalizing patient treatment strategies," said John Jefferies, Daxor's Chief Medical Officer.
“The continued sales growth that the company is experiencing has positioned us for our best quarter ever in terms of revenue and year-over-year growth reflecting the focus of our commercialization team and the increasing customer engagement driven by our clinical education team,” said Michael Feldschuh, Daxor’s CEO and President.
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100™ (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com
FAQ
What new healthcare systems has Daxor (DXR) expanded its BVA-100 diagnostic to in December 2023?
How does Daxor's ezBVA Lab service benefit healthcare providers?
What is the financial impact of the new expansions on Daxor (DXR)?
What medical applications is Daxor's BVA-100 being implemented for in the new health systems?
